Atai Beckley NV
Atai Beckley NV Q2 FY2022 earnings call
August 15, 2022 · fiscal period ended 2022-06
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2022-08-15
Management highlights
- Extended runway to 2025 with $312 million cash and $175 million Hercules debt facility.
- Prioritized pipeline to focus on clinical programs with proof-of-concept data inflections within two years.
- Three-pillar strategy includes differentiated pharmacology, digital therapeutics for psychotherapeutic support, and precision psychiatry via digital phenotyping and biomarkers.
- Active in BD/M&A, seeking assets to accelerate pipeline or complement existing programs.
- Details on specific programs: PCN-101 trial design, U.S. expansion, subcu formulation, DDI study; RL-007's polypharmacology, clinical trial design, and dosing profile improvement.
Segment performance
No specific product segment financial performance data provided in the transcript.
Guidance
- Runway extended to 2025, no additional funding anticipated for current POC readouts.
- Focus on clinical programs with POC data expected within two years.
Q&A highlights
Q: Judah Frommer asks about capital allocation priorities and how runway factors in.
A: Florian Brand states runway extended to 2025 due to non-dilutive financing and pipeline reprioritization, no additional funding needed for POC readouts.
Q: Andrew Tsai asks about following COMPASS' footsteps.
A: Srini Rao and Florian Brand discuss digital tools and trial designs aligning with COMPASS' approach.
Q: Judah Frommer asks about COMPASS' Phase 3 trial design implications.
A: Srini Rao talks about digital components and trial design aspects relevant to Atai's pipeline.
Q: Andrew Tsai asks about FDA's view on COMPASS' Phase 2b as pivotal.
A: Srini Rao is skeptical but awaits data on COMPASS' Phase 3 trial design.
Q: Judah Frommer asks about PCN-101 design, timelines, and success criteria.
A: Srini Rao details PCN-101 trial design, U.S. expansion, subcu formulation, and DDI study status.
Q: Andrew Tsai asks about approvability delta for PCN-101.
A: Srini Rao discusses delta and at-home use considerations for PCN-101.
Q: Judah Frommer asks about RL-007 and CIAS.
A: Srini Rao talks about RL-007's polypharmacology, clinical trial design, and challenges in CIAS.
Q: Judah Frommer asks about RL-007 dosing profile and next steps.
A: Srini Rao talks about Phase 2b endpoint and posology improvement for RL-007
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $-0.24 | $-0.22 | -9.1% | $-0.31 |
| Revenue | $170,000 | — | — | — |
Transcript
August 15, 2022Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.